Indication: Galcanezumab-gnlm (Emgality) is a calcitonin-gene related peptide (CGRP) antagonist indicated in adults for the preventive treatment of migraine and treatment of episodic cluster headache.

Insight:

Dosing: Migraine recommended dosage 240 mg loading dose, administered as 2 consecutive injections of 120 mg each, followed by monthly doses of 120 mg.

Dosage forms: Injection 120 mg/mL solution in a single-dose prefilled pen.

Adverse events: The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Mechanism of action: Galcanezumab-gnlm is a humanized monoclonal antibody that binds to the CGRP ligand and blocks its binding to the receptor.

Manufacturer: Eli Lilly

References:

These highlights do not include all the information needed to use EMGALITY safely and effectively. See full prescribing information for EMGALITY.EMGALITY (galcanezumab-gnlm) injection, for subcutaneous useInitial U.S. Approval: 2018 (lilly.com)
emgality image - Google Search